Lipocine Reports Positive Interim Safety Data for LPCN 1154 in Postpartum Depression Trial

Lipocine has completed an independent Data Safety Monitoring Board review of its Phase 3 trial for LPCN 1154, an oral brexanolone treatment for postpartum depression. The review found a promising interim safety profile, with no treatment discontinuations or serious adverse events reported. The trial, which is evaluating LPCN 1154 in women with severe PPD, is expected to continue without modification.